Assetmark Inc. Has $75,000 Stock Position in Globus Medical, Inc. $GMED

Assetmark Inc. cut its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 88.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,314 shares of the medical device company’s stock after selling 10,459 shares during the quarter. Assetmark Inc.’s holdings in Globus Medical were worth $75,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Boston Trust Walden Corp bought a new position in Globus Medical during the third quarter worth $67,891,000. Norges Bank acquired a new stake in Globus Medical in the 2nd quarter worth $68,038,000. Marshall Wace LLP increased its holdings in shares of Globus Medical by 89.7% during the 2nd quarter. Marshall Wace LLP now owns 1,580,476 shares of the medical device company’s stock worth $93,280,000 after purchasing an additional 747,330 shares during the period. Burgundy Asset Management Ltd. raised its position in shares of Globus Medical by 24.3% during the second quarter. Burgundy Asset Management Ltd. now owns 3,481,438 shares of the medical device company’s stock valued at $205,474,000 after buying an additional 679,691 shares during the last quarter. Finally, Sculptor Capital LP raised its position in shares of Globus Medical by 31.9% during the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after buying an additional 667,850 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical Price Performance

NYSE GMED opened at $92.01 on Wednesday. The stock’s 50 day simple moving average is $90.10 and its 200 day simple moving average is $75.84. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The firm has a market cap of $12.31 billion, a PE ratio of 29.68, a price-to-earnings-growth ratio of 1.43 and a beta of 1.06.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.22. The firm had revenue of $826.42 million during the quarter, compared to the consensus estimate of $803.29 million. Globus Medical had a return on equity of 11.52% and a net margin of 15.30%.The business’s revenue for the quarter was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.84 EPS. As a group, equities analysts expect that Globus Medical, Inc. will post 3.44 earnings per share for the current year.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q4 revenue and adjusted results beat expectations — Globus reported Q4 net sales of $826.4M (+25.7% YoY) and strong adjusted EBITDA/non‑GAAP EPS, driven in part by the Nevro contribution and base business strength. GlobeNewswire Release
• Positive Sentiment: Raised non‑GAAP EPS guidance for 2026 and reconfirmed revenue range — management updated 2026 non‑GAAP EPS to $4.40–$4.50 and reaffirmed revenue of $3.18–$3.22B, signalling confidence in integration and margin leverage. Guidance / Release
• Positive Sentiment: Profitability expansion — company posted record non‑GAAP EPS and sizable increases in gross profit and operating profit, reflecting synergies from acquisitions and cost discipline. Quiver Quant Summary
• Neutral Sentiment: Investor materials and call scheduled — management held a conference call and published detailed GAAP/non‑GAAP reconciliations; listen/transcript available for further color on sustainability of margins. Press Release / Call Materials
• Neutral Sentiment: Wide analyst interest and price‑target dispersion — multiple firms maintain buy/overweight ratings with median targets near $100, but targets vary, so consensus reaction may diverge. Quiver – Analyst Snapshot
• Negative Sentiment: GAAP vs non‑GAAP earnings confusion — GAAP diluted EPS was $1.03 while non‑GAAP EPS was $1.28; some outlets reported an EPS “miss” on GAAP or different consensus metrics, creating headline risk and mixed press coverage. Quiver – EPS Detail
• Negative Sentiment: Growth concentrated in recent acquisitions — base business (ex‑Nevro) grew only ~5% for the year, raising questions about how much of future upside will rely on further M&A versus organic acceleration. Quiver – Business Mix
• Negative Sentiment: Cash and capital deployment concerns plus insider selling — cash and equivalents fell to ~$526M, capex and acquisitions were sizable, and recent insider sales were noted by data providers, which can pressure sentiment. Quiver – Cash & Insider Activity

Insider Activity at Globus Medical

In other Globus Medical news, EVP Kelly Huller sold 10,000 shares of the firm’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $87.67, for a total value of $876,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leslie V. Norwalk sold 2,000 shares of the business’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $202,200.00. Following the completion of the transaction, the director directly owned 10,419 shares of the company’s stock, valued at approximately $1,053,360.90. This represents a 16.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 34,136 shares of company stock valued at $3,111,033 over the last ninety days. 18.54% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Zacks Research lowered Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 9th. Bank of America raised Globus Medical from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $65.00 to $91.00 in a report on Friday, November 7th. Truist Financial restated a “buy” rating and set a $105.00 price objective (up from $93.00) on shares of Globus Medical in a research report on Tuesday, November 18th. Royal Bank Of Canada upped their target price on Globus Medical from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Finally, Wells Fargo & Company lifted their price target on shares of Globus Medical from $66.00 to $79.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Globus Medical currently has an average rating of “Moderate Buy” and an average target price of $100.18.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.